Brainscape's Knowledge GenomeTM

Browse over 1 million classes created by top students, professors, publishers, and experts.


See full index

Hematology > Platelets > Flashcards

Platelets Flashcards

1
Q

HIT: risk factors (3)

A
  • Unfractionated heparin > LMWH - Therapeutic dose > Prophylactic dose - Bovine > Porcine
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

Which anti-thrombotic agents can be substituted for heparin after a diagnosis of HIT (3)?

A

Lepirudin Argatroban Fondaparinux

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

What are the 2 diagnostic tests available for HIT?

A
  • ELISA - Platelets 14C serotonin release assay
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

5 drugs leading to thrombopenia

A
  • Sulfas - Penicillin - Quinines - Procainamide - Levodopa - Gold salts - Interferon alfa
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

What is Upshaw-Schulman syndrome?

A

Congenital TTP, caused by mutation (AR) in ADAMTS13

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

How is confirmed the diagnosis of TTP?

A
  • Confirmation of decreased ADAMTS13 activity - Screening for anti-ADAMTS13 auto-Ab
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

TTP: - How many are secondary? - Name 3 causes of secondary TTP

A
  • 15% - Pregnancy, drugs, infections (viral or bacterial), collagen vascular disorders, malignancy, pancreatitis
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

TTP treatment a) Congenital b) Acquired

A

a) Prophylactic FFP infusions b) Plasma exchange; Glucocorticoids often given as adjunct, although advantage not proven Rituximab for refractory cases

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

Which lesions are associated with Kasabach-Merritt phenomenom?

A

Tufted angioma Kaposiform hemangioendothelioma

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q
  • Diagnosis? - Non MSK complications
A

Osteopetrosis Syndrome associated with osteoclasts dysfunction, leading to impaired bone modelling and repair Leads to skeletal fragility despite increased bone mass and hematopoietic insufficiency, delayed tooth eruption, nerve entrapment syndrome, short stature

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

Osteopetrosis: treatment options

A

Only curative option: HSCT, to be done ASAP re: neurological impairment early in course of disease and often irreversible

Calcitriol, IFN-gamma and prednisone can slow down progression

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

NAIT:

  • Risk for future pregnancies
  • how should future pregnancies be managed?
A
  • Usually severity of NAIT increases with each pregnancy
  • Percutaneous umbilical cor sampling @ 20-22 weeks for fetal platelet count and platelet antigen typing
    Maternal IVIG weekly
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

NAIT: what proportion of patients develop ICH?

What other Sx are seen?

A

15% (including 50% in utero)

Petechias, hematomas, GI bleeding

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

NAIT: what is the duration of the thrombopenia?

A

3-4 weeks

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

Name 3 sides effects of TPO agonists, using in the treatment of ITP

A

Elthrombopag: hepatotoxicity

Both: myelofibrosis and thrombo-embolic events (adult studies, seems well tolerated in children)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

Name 5 situations where ALPS should be investigated?

A
  • Unexplained auto-immune disease
  • Auto-immune disease affecting at least 2 organs
  • Unexplained lymphoproliferation
  • Cytopenias of at least 2 lineages
  • Single cytopenia withhypergammaglobulinemia

-

17
Q

What are the 2 required features required for a diagnosis of ALPS?

A
  1. Lymphadenopathy and/or splenomegaly of non-infectious origin
    for at least 6 months
  2. Elevated double-negative alpha/beta T-cells
    (i. e. > 1.5% of T-lymphocytes or >2.5% of all lymphocytes)
18
Q

What genetic mutations are associated with ALPS?

A

FAS, FASL, CASP10

19
Q

How is the diagnosis of BSS confirmed?

A
  1. Platelet aggregation test: failure to agglutinate in presence of ristocetine; otherwise normal aggregation with other agonists
  2. Flow cytometry: decreased expression of GP1B/IX complex
  3. Molecular studies: mutation of GP1BA, GP1BB, GP9
20
Q

What is contained in:

  • Alpha granules?
  • Delta granules?
A
  • Alpha: “the big stuff” such as prothrombotic and proangiogenic factors and antithrombotic and antiangiogenic factors e.g. VWF, thrombospondin, PF4
  • Delta: small molecules e.g. calcium, serotonin, ADP, ATP, etc.
21
Q

Hernansky-Pudlak syndrome

  • Associated mutations?
  • Populations at risk
A
  • HPS1 to 9 (autosomal recessive)
  • High frequencies in certain populations, e.g. Puerto Rico
22
Q

Clinical features associated with Hermansky-Pudlak syndrome (6)

A
  • Oculo-cutaneous albinism
  • Visual features: decreased visual acuity, photophobia, rotatory nystagmus
  • Mild to moderate bleeding diathesis, following a storage pool disorder
  • Granulomatous colitis
  • Pulmonary fibrosis (HPS 1 & 4)
  • Neutropenia (HPS 2)
23
Q

Dense granules defects:

  • Name 3 examples
A
  1. Hermansky-Pudlak syndrome
  2. Chediak-Higashi
  3. Griscelli
24
Q

Describe diagnostic tests specific for dense granules defects

A
  • Whole-mount microscopy
  • Serotonin release assays or ATP/ADP release assays
25
Q

Which clinical features are associated with Griscelli syndrome?

A
  • Silver hair
  • Partial albinism
  • Mild bleeding diathesis (plt function disorder)
  • Neurologic defects
  • Lymphohistiocytosis

Bonus! Associated mutation: RAB27A

26
Q

List 2 disorders marked by alpha-granules defect?

A
  1. Gray platelet syndrome (NBEAL mutations)
  2. ARC: arthrogryposis, renal dysfunction, cholestasis syndrome (VPS33B or VPS16B mutation)
27
Q

Name mutations associated with essential thrombocytosis (3)

A
  • JAK 2
  • CALR
  • MPL
28
Q

What treatment modalities are available for essential thrombocytosis?

A
  • Low dose aspirin
  • Cytoreductive therapies: hydroxyurea, interferon-alpha
29
Q

Work up thrombocytosis

A
  • CBC
  • Peripheral smear
  • CRP
  • Iron work up
  • BCR-ABL1 rearrangement
  • Mutation status for JAK2, CALR, MPL
  • Bone marrow aspirate and biopsy
30
Q

3 complications associated with ET

A
  1. Vascular events (10-25% thrombosis at 15y)
  2. Progression to myelofibrosis (10% at 15y)
  3. Leukemic transformation (3% at 15y)

Hematology (6 decks)

Brainscape helps you reach your goals faster, through stronger study habits.
© 2024 Bold Learning Solutions. Terms and Conditions